Pfizer Announces Search for New Chief Financial Officer

Editor’s Take: Denton leaves large shoes to fill, since he helped lead Pfizer through some of the most important business transactions in its recent history, including the Seagen, Biohaven and Metsera acquisitions.

Pfizer Inc.’s Chief Financial Officer, Dave Denton, is stepping down from his current role and leaving the company on August 15 for a “professional opportunity outside of the pharmaceutical industry,” which he has accepted. Meanwhile, the company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfizer conducts a comprehensive internal and external search.

“Dave has been a steady and trusted steward of Pfizer’s financial health, and we are grateful for his leadership,” remarked Albert Bourla, Chairman and Chief Executive Officer. “We wish him the very best as he returns to the consumer goods industry.”

Interim CFO, Cecile Guegan

Guegan brings more than two decades of experience at Pfizer, amassing global financial experience leading finance across a wide range of complex and strategic portfolios, research and development, and several regions.

In her current role, Guegan is directly responsible for the financial operations and reporting of Pfizer’s biopharmaceutical business across all therapeutic areas and geographies. She holds a Master in Business degree from Brest Business School.

“Given Cecile’s deep institutional knowledge and financial acumen, I have every confidence in her ability to lead Pfizer’s finance organization and keep us focused on what matters most — executing our strategy and delivering for patients and shareholders,” said Bourla.